Patient characteristics
| . | Group I: unselected PBPCTs (n = 19) . | Group II: CD34+-selected PBPCTs (n = 18) . | Group III: BMT from an unrelated donor (n = 15) . |
|---|---|---|---|
| Median age (y), (range) | 45 (31-56) | 42 (19-53) | 36 (24-51) |
| Sex (no. females/no. males) | 8/11 | 4/14 | 3/12 |
| Underlying disease | |||
| ALL | 1 | 3 | 4 |
| AML | 8 | 8 | 6 |
| MPS | 2 | 1 | 2 |
| MDS/sAML | 3 | 5 | 1 |
| Lymphoma | 5 | 1 | 1 |
| SAA | 0 | 0 | 1 |
| Conditioning therapy | |||
| Chemo + TBI | 5 | 8 | 11 |
| Chemo only | 14 | 10 | 4 |
| HLA compatibility | |||
| HLA identical | 19 | 15 | 11 |
| 1 antigen-mismatch | 3 | 4 | |
| CMV serostatus | |||
| R+/D+ | 9 | 13 | 6 |
| R+/D− | 3 | 2 | 7 |
| R−/D+ | 7 | 3 | 2 |
| CMV infection | 12 | 16 | 15 |
| CMV disease | 1 | 2 | 3 |
| . | Group I: unselected PBPCTs (n = 19) . | Group II: CD34+-selected PBPCTs (n = 18) . | Group III: BMT from an unrelated donor (n = 15) . |
|---|---|---|---|
| Median age (y), (range) | 45 (31-56) | 42 (19-53) | 36 (24-51) |
| Sex (no. females/no. males) | 8/11 | 4/14 | 3/12 |
| Underlying disease | |||
| ALL | 1 | 3 | 4 |
| AML | 8 | 8 | 6 |
| MPS | 2 | 1 | 2 |
| MDS/sAML | 3 | 5 | 1 |
| Lymphoma | 5 | 1 | 1 |
| SAA | 0 | 0 | 1 |
| Conditioning therapy | |||
| Chemo + TBI | 5 | 8 | 11 |
| Chemo only | 14 | 10 | 4 |
| HLA compatibility | |||
| HLA identical | 19 | 15 | 11 |
| 1 antigen-mismatch | 3 | 4 | |
| CMV serostatus | |||
| R+/D+ | 9 | 13 | 6 |
| R+/D− | 3 | 2 | 7 |
| R−/D+ | 7 | 3 | 2 |
| CMV infection | 12 | 16 | 15 |
| CMV disease | 1 | 2 | 3 |
All entries are numbers of patients unless otherwise indicated.
PBPCTs, peripheral blood progenitor cell transplants; BMT, bone marrow transplantation; F, female; M, male; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MPS, myeloproliferative syndrome; MDS, myelodysplastic syndrome; sAML, secondary acute myeloid leukemia; SAA, severe aplastic anemia; Chemo, chemotherapy; TBI, total body irradiation; R, recipient; D, donor; HLA, human leukocyte antigen.